annb0t
Top 20
Trial met primary and secondary endpoints and confirmed favourable safety and tolerability profile, indicating TLX250-CDx has the potential to become a new clinical standard in the identification and characterisation of clear cell renal cell carcinoma (ccRCC):
Primary endpoint met: Sensitivity of â¥84% and specificity of â¥84% in all three readers (86% / 87% overall) Considerably exceeds confirmatory trial sensitivity and specificity success targets Key secondary endpoints met, achievi...
>>> Read more: Detailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU
Primary endpoint met: Sensitivity of â¥84% and specificity of â¥84% in all three readers (86% / 87% overall) Considerably exceeds confirmatory trial sensitivity and specificity success targets Key secondary endpoints met, achievi...
>>> Read more: Detailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU
